Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
142 hedge funds and large institutions have $431M invested in Sciclone Pharmaceuticals Inc in 2016 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 54 reducing their positions, and 14 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
86% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 14
26% more capital invested
Capital invested by funds: $341M → $431M (+$89.9M)
7% more funds holding
Funds holding: 133 → 142 (+9)
17% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 54
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $324K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$12.9M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$7.76M |
| 3 |
Renaissance Technologies
New York
|
+$3.11M |
| 4 |
Millennium Management
New York
|
+$2.35M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.24M |
| 2 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$2.61M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.97M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.78M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DC
151
Davenport & Co
Richmond,
Virginia
| – | -$105K | -11,400 | Closed |
|
|
QI
152
Quotient Investors
New York
| – | -$96K | -10,391 | Closed |
|
|
BA
153
Boston Advisors
Boston,
Massachusetts
| – | -$95K | -10,373 | Closed |
|
154
BNP Paribas Financial Markets
Paris,
France
| – | -$85.9K | -9,340 | Closed |
|
|
TRCT
155
Tower Research Capital (TRC)
New York
| – | -$52.6K | -5,912 | -99% |
|
|
IA
156
IFP Advisors
Tampa,
Florida
| – | -$5K | -500 | Closed |
|
SCLN Hedge Fund Activity: Q1 2016 in Review
142 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q1 2016, worth a combined $431M — up 26% from $341M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SCLN positions and 14 closed out — a net gain of 12 holders — while 45 added to existing stakes and 54 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $12.9M. The largest seller was Morgan Stanley, cutting an estimated $3.24M.
- 142 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q1 2016, up from 133 in Q4 2015.
- Funds reported $431M of Sciclone Pharmaceuticals Inc stock for Q1 2016, up 26% quarter-over-quarter.
- 26 funds opened new Sciclone Pharmaceuticals Inc positions in Q1 2016 and 14 closed out, a net change of +12 holders.
- The largest Sciclone Pharmaceuticals Inc buyer in Q1 2016 was Nantahala Capital Management, an estimated $12.9M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q1 2016 was Morgan Stanley, an estimated $3.24M sold.
Based on aggregated 13F filings for Q1 2016.